Foundayo

CVS will restore Zepbound coverage on October 1 and add Eli Lilly's newly approved Foundayo obesity pill to drug plans starting June 1. This expanded coverage could significantly increase market access for weight management medications.

The FDA approved Eli Lilly's GLP-1 pill Foundayo, entering the oral weight loss drug market three months after Novo Nordisk's oral Wegovy launch. This creates competition in the rapidly growing weight loss pharmaceutical market.